Marinus Pharmaceuticals, Inc.
MRNSDelisted Feb 11, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001267813
Marinus Pharmaceuticals, Inc. was delisted on Feb 11, 2025; its insiders filed their last Form 4 on Feb 11, 2025; 53 institutions reported holding it in 13F filings for Q4 2024, worth $15.8M in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Marinus Pharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +2 vs. Q3 2023
- Shares held
- 53.8M
- +3.07M (+6.0%) vs. Q3 2023
- Total value
- $585.2M
- +$176.4M (+43.2%) vs. Q3 2023
- New holders
- 21
- 35 more added
- Sold out
- 19
- 33 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MRNS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 53 | $15.8M |
| Q3 2024 | 75 | $72.9M |
| Q2 2024 | 90 | $50.6M |
| Q1 2024 | 112 | $486.5M |
| Q4 2023 | 105 | $585.2M |
| Q3 2023 | 104 | $411.1M |
| Q2 2023 | 106 | $485.0M |
| Q1 2023 | 86 | $283.9M |
| Q4 2022 | 74 | $165.6M |
| Q3 2022 | 69 | $186.9M |
| Q2 2022 | 73 | $140.6M |
| Q1 2022 | 83 | $280.4M |
| Q4 2021 | 75 | $355.7M |
| Q3 2021 | 82 | $362.0M |
| Q2 2021 | 80 | $563.3M |
| Q1 2021 | 87 | $480.3M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Marinus Pharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 3,250,000 | $35.3M | 1.69% | +625,000+23.8% | Added |
| Franklin Resources Inc | 3,833,955 | $41.7M | 0.02% | +49,589+1.3% | Added |
| Eventide Asset Management, LLC | 4,529,997 | $49.2M | 0.80% | 00.0% | Unchanged |
| BlackRock Inc. | 4,599,278 | $50.0M | 0.00% | +453,635+10.9% | Added |
| Suvretta Capital Management, LLC | 5,346,119 | $58.1M | 2.66% | +141,177+2.7% | Added |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −253,412−100.0% | Sold out |
| Putnam Investments LLC | 0 | $0 | 0.00% | −51,708−100.0% | Sold out |
| Worth Venture Partners, LLC | 0 | $0 | 0.00% | −42,400−100.0% | Sold out |
| Moore Capital Management, LP | 0 | $0 | 0.00% | −31,181−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −19,725−100.0% | Sold out |
| Acuta Capital Partners, LLC | 0 | $0 | 0.00% | −19,500−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −17,539−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −16,200−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −15,873−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −13,202−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −11,400−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −7,895−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −5,094−100.0% | Sold out |
| BluePath Capital Management, LLC | 0 | $0 | 0.00% | −4,730−100.0% | Sold out |
| Impact Partnership Wealth, LLC | 0 | $0 | 0.00% | −749−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −60−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −38−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| International Biotechnology Trust PLC | – | – | – | – | Not filed |